CR20150569A - Composiciones y métodos para el virus del dengue construcciones quiméricas en las vacunas - Google Patents

Composiciones y métodos para el virus del dengue construcciones quiméricas en las vacunas

Info

Publication number
CR20150569A
CR20150569A CR20150569A CR20150569A CR20150569A CR 20150569 A CR20150569 A CR 20150569A CR 20150569 A CR20150569 A CR 20150569A CR 20150569 A CR20150569 A CR 20150569A CR 20150569 A CR20150569 A CR 20150569A
Authority
CR
Costa Rica
Prior art keywords
dengue
virus
compositions
vaccines
methods
Prior art date
Application number
CR20150569A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Claire Kinney
Richard M Kinney
Jill A Livengood
Original Assignee
Takeda Vaccines Inc
Us Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc, Us Government filed Critical Takeda Vaccines Inc
Publication of CR20150569A publication Critical patent/CR20150569A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones, usos y manufactura de construcciones del virus del dengue y virus del dengue vivos atenuados. En ciertas modalidades, la composición puede incluir, pero no se limita a una composición tetravalente del virus del dengue. En ciertas modalidades, las composiciones pueden incluir construcciones de uno o más serotipos del virus del dengue, tales como las construcciones del virus dengue-I (DEN-1, el virus dengue-2 (DEN-2), los virus dengue-3 (DEN-3) o dengue-4 (DEN-4) .
CR20150569A 2013-03-15 2015-10-15 Composiciones y métodos para el virus del dengue construcciones quiméricas en las vacunas CR20150569A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361800204P 2013-03-15 2013-03-15
PCT/US2014/024603 WO2014150939A2 (en) 2013-03-15 2014-03-12 Compositions and methods for dengue virus chimeric constructs in vaccines

Publications (1)

Publication Number Publication Date
CR20150569A true CR20150569A (es) 2016-04-01

Family

ID=50678274

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150569A CR20150569A (es) 2013-03-15 2015-10-15 Composiciones y métodos para el virus del dengue construcciones quiméricas en las vacunas

Country Status (32)

Country Link
US (5) US9783579B2 (es)
EP (5) EP3689374B1 (es)
JP (2) JP6818548B2 (es)
KR (3) KR102626270B1 (es)
CN (5) CN113637694A (es)
AR (2) AR095598A1 (es)
AU (2) AU2014235476B2 (es)
CA (4) CA3177574A1 (es)
CR (1) CR20150569A (es)
DK (1) DK4129330T3 (es)
DO (1) DOP2015000232A (es)
EC (1) ECSP23013715A (es)
ES (2) ES2933970T3 (es)
FI (2) FI3539565T3 (es)
FR (1) FR22C1064I1 (es)
HK (1) HK1220359A1 (es)
HR (1) HRP20231581T1 (es)
HU (2) HUE061507T2 (es)
LT (1) LT4129330T (es)
MX (5) MX2015012893A (es)
MY (1) MY187796A (es)
NL (1) NL301223I2 (es)
NZ (1) NZ630869A (es)
PE (2) PE20211814A1 (es)
PH (1) PH12015502120A1 (es)
PL (1) PL3539565T3 (es)
PT (1) PT3539565T (es)
SG (3) SG10201913435TA (es)
SI (1) SI4129330T1 (es)
TW (3) TWI726312B (es)
UY (1) UY35489A (es)
WO (1) WO2014150939A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2933970T3 (es) 2013-03-15 2023-02-15 Takeda Vaccines Inc Composiciones y métodos para construcciones quiméricas de virus del dengue en vacunas
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
EP3382012A4 (en) * 2015-11-27 2019-07-03 KM Biologics Co., Ltd. LIVE VIRUS COMPRISING A BANK OF DENGUE-VIRUS-DENGED STRAINS, AND DENGUE VACCINE CONTAINING THE DENGUE AS ANTIGENS
MX2018012459A (es) 2016-04-13 2019-06-06 Takeda Vaccines Inc Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes.
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276941A (en) 1975-12-23 1977-06-28 Ito Masato Method of conversing infrared rays
US4810092A (en) 1986-02-21 1989-03-07 Midac Corporation Economical spectrometer unit having simplified structure
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
DE69231570T2 (de) 1991-09-19 2001-06-21 Us Health Chimäre und/oder wachstumgehemmte Flaviviren
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
CA2224724C (en) 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
IL131600A0 (en) 1997-02-28 2001-01-28 Ora Vax Inc Chimeric flavivirus vaccines
AU9794198A (en) 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric vaccine against tick-borne encephalitis virus
CA2331368C (en) 1998-06-04 2009-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
PT2278012E (pt) 2000-02-16 2015-11-30 Univ Mahidol Quimeras imunogénicas do vírus do dengue 2
PT1159968E (pt) * 2000-05-30 2008-11-20 Univ Mahidol Estirpes atenuadas de vírus do dengue e a sua utilização numa composição de vacina
CA2440593A1 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
WO2006134443A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 2 attenuated strain
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
KR20070017759A (ko) 2005-08-08 2007-02-13 삼성전자주식회사 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법
WO2007021672A2 (en) * 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
PL2589602T3 (pl) * 2006-08-15 2016-11-30 Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi
AP3172A (en) 2007-07-13 2015-03-31 Florida Gulf Coast University Optimized dengue virus entry inhibitory peptide (DN81)
BRPI0913012B1 (pt) * 2008-04-30 2021-12-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Quimera de ácido nucleico, métodos para detectar um anticorpo do vírus da dengue em uma amostra de um paciente, e para produzir partículas virais que expressam proteínas prm e e do vírus da dengue, uso de vírus codificado pela quimera e flavivírus ou partícula viral quiméricos
SG157244A1 (en) 2008-05-15 2009-12-29 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure or immunity to dengue virus
JP5276941B2 (ja) 2008-09-24 2013-08-28 株式会社村田製作所 大変位アクチュエータ
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2438198A4 (en) 2009-06-01 2014-05-14 Inviragen Inc COMPOSITIONS AND METHODS FOR THE DELIVERY OF VACCINES AGAINST DENGUE VIRUS
CN101560520A (zh) * 2009-06-04 2009-10-21 中国疾病预防控制中心病毒病预防控制所 乙脑/登革嵌合病毒及其应用
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
TW201402143A (zh) 2012-06-10 2014-01-16 Inviragen Inc 抗登革熱病毒疫苗之組成物及投藥方法
CN104812408A (zh) 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 用于防止登革热病毒感染的疫苗组合物
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
TW201428101A (zh) * 2012-11-08 2014-07-16 Inviragen Inc 登革熱病毒血清型４型之建構物的組成物、方法及用途
CA2933472A1 (en) * 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
ES2933970T3 (es) 2013-03-15 2023-02-15 Takeda Vaccines Inc Composiciones y métodos para construcciones quiméricas de virus del dengue en vacunas
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
MX2018012459A (es) 2016-04-13 2019-06-06 Takeda Vaccines Inc Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes.
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
AU2018352447A1 (en) 2017-10-16 2020-06-11 Serum Institute Of India Private Limited Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Also Published As

Publication number Publication date
SG10201913387XA (en) 2020-02-27
JP2019146594A (ja) 2019-09-05
EP3689374B1 (en) 2022-11-02
AU2019216724B2 (en) 2021-03-04
EP4183411A1 (en) 2023-05-24
AU2019216724A1 (en) 2019-09-05
HRP20231581T1 (hr) 2024-03-15
CN105451763B (zh) 2021-06-18
MX2023000353A (es) 2023-02-13
MX2023000349A (es) 2023-04-24
TWI726312B (zh) 2021-05-01
CA3166063A1 (en) 2014-09-25
US20220062375A1 (en) 2022-03-03
NZ630869A (en) 2017-11-24
JP7050031B2 (ja) 2022-04-07
BR122021015502A2 (pt) 2021-12-14
PT3539565T (pt) 2023-04-12
AR095598A1 (es) 2015-10-28
ES2933970T3 (es) 2023-02-15
LT4129330T (lt) 2023-12-27
CA3177572A1 (en) 2014-09-25
EP3539565A1 (en) 2019-09-18
CN113637086A (zh) 2021-11-12
KR20240014580A (ko) 2024-02-01
TW201516147A (zh) 2015-05-01
SI4129330T1 (sl) 2024-02-29
BR112015023635A2 (pt) 2018-06-05
KR102389908B1 (ko) 2022-04-26
BR112015023635A8 (pt) 2021-12-14
SG10201913435TA (en) 2020-03-30
EP3689374A1 (en) 2020-08-05
HUE061507T2 (hu) 2023-07-28
CA2903231A1 (en) 2014-09-25
US20200061151A1 (en) 2020-02-27
MY187796A (en) 2021-10-24
HUS2300022I1 (hu) 2023-08-28
EP2968516B1 (en) 2022-01-12
DK4129330T3 (da) 2023-12-11
US20230181682A1 (en) 2023-06-15
PE20211814A1 (es) 2021-09-14
CN111778263A (zh) 2020-10-16
BR122021015503A2 (pt) 2021-12-14
KR102626270B1 (ko) 2024-01-19
ES2965652T3 (es) 2024-04-16
FR22C1064I1 (fr) 2023-02-03
NZ735336A (en) 2021-04-30
FI3539565T3 (fi) 2023-04-19
PL3539565T3 (pl) 2023-09-25
CN105451763A (zh) 2016-03-30
KR20160002780A (ko) 2016-01-08
TW202144573A (zh) 2021-12-01
EP4129330A1 (en) 2023-02-08
WO2014150939A3 (en) 2014-12-31
MX2019003602A (es) 2022-06-27
US10449231B2 (en) 2019-10-22
US20170290884A1 (en) 2017-10-12
WO2014150939A2 (en) 2014-09-25
NL301223I2 (nl) 2023-07-26
US20140302088A1 (en) 2014-10-09
JP2016513970A (ja) 2016-05-19
CN113637694A (zh) 2021-11-12
MX2015012893A (es) 2016-04-04
CA3177574A1 (en) 2014-09-25
PE20160027A1 (es) 2016-01-28
US9783579B2 (en) 2017-10-10
JP6818548B2 (ja) 2021-01-20
CN113637693A (zh) 2021-11-12
TWI733646B (zh) 2021-07-21
DOP2015000232A (es) 2016-02-29
AR123702A2 (es) 2023-01-04
FIC20230021I1 (fi) 2023-06-27
ECSP23013715A (es) 2023-04-28
MX2023000354A (es) 2023-02-13
UY35489A (es) 2014-10-31
HK1220359A1 (zh) 2017-05-05
SG11201507460PA (en) 2015-10-29
AU2019216724C1 (en) 2021-08-26
AU2014235476A1 (en) 2015-09-24
EP3539565B1 (en) 2023-01-11
KR20220054892A (ko) 2022-05-03
EP4129330B1 (en) 2023-09-06
TW201945545A (zh) 2019-12-01
US11931399B2 (en) 2024-03-19
AU2014235476B2 (en) 2019-05-16
PH12015502120A1 (en) 2016-01-25
EP2968516A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
CO2018011355A2 (es) Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
CR11737A (es) Polipéptidos modificados del factor ix y usos de los mismos
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
PE20151769A1 (es) Variantes de pertuzumab y su evalaucion
UY37360A (es) Nucleósidos sustituidos, nucleótidos y análogos de estos
UY33924A (es) Compuestos de triazolopiridina como inhibidores de cinasa pim
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
CL2013000714A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
CO6470882A2 (es) Composiciones y metodos para administración de vacunas contra virus del dengue.
PE20110992A1 (es) Composicion inmunogenica que comprende un antigeno del virus del dengue
GT201200023A (es) Polipéptidos del factor ix modificados y usos de los mismos
UY34066A (es) Inhibidores del virus de la hepatitis c
WO2015095735A3 (en) Vaccine compositions and uses thereof
WO2012065105A3 (en) Chimeric flavivirus vaccines
CL2011002619A1 (es) Compuestos derivados de arilsulfonamidas, moduladores de la actividad del receptor ccr3; composición farmacéutica que los comprende; utiles en el traramiento de una enfermedad inflamatoria tal como asma, rinitis alergica, dermatitis atopica, epoc entre otras.
PH12021550785A1 (en) Virus vaccine
CR20120166A (es) Composiciones y productos antimicrobianos
TH170668A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน
DK2490667T3 (da) Sammensætning, der omfatter solanum glaucophyllum, til forebyggelse og/eller behandling af hypocalcæmi og til stabilisering af blodcalciumniveauer
CO2021017772A2 (es) Virus del dengue atenuados